A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Clinical trial NCT03525613 · COMPLETED
Trial details
- NCT number
- NCT03525613
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-31
- Primary completion
- 2021-06-28
- Enrollment
- 637
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.